Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M D Michaelson

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Neuron|December 1, 1993
Cytokine-induced programmed death of cultured sympathetic neuronsJ A Kessler, W H Ludlam, M M Freidin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinomaS Négrier, A G Bushmakin, J C Cappelleri, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
British Journal of Cancer|March 21, 2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyM D Michaelson, A X Zhu, D P Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancerM D Michaelson, J Bellmunt, G R Hudes, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Neuron|December 1, 1993
Cytokine-induced programmed death of cultured sympathetic neuronsJ A Kessler, W H Ludlam, M M Freidin, et al.
European Journal of Cancer (Oxford, England : 1990)|April 29, 2014
Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinomaS Négrier, A G Bushmakin, J C Cappelleri, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
British Journal of Cancer|March 21, 2013
Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding studyM D Michaelson, A X Zhu, D P Ryan, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 21, 2011
Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancerM D Michaelson, J Bellmunt, G R Hudes, et al.
British Journal of Cancer|May 15, 2014
Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trialB Escudier, M D Michaelson, R J Motzer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 23, 2023
The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinomaB A McGregor, G P Sonpavde, L Kwak, et al.
Pageof 2